Neoadjuvant SHR-A1811 showed similar pathologic complete response rates to the standard 4-drug regimen in patients with ...

Survival according to treatment group and complete pathologic response (pT0) in patients treated with either neoadjuvant MVAC and cystectomy or cystectomy alone. Hazard ratios for subgroups ...

Published in Clinical Cancer Research, results of a VHIO-led study underscore the potential of the RAD51 biomarker in ...

Findings from the HELEN-006 trial suggest a potential shift in neoadjuvant treatment practices for patients with HER2-positive early breast cancer, specifically using nab-paclitaxel to reduce ...

Surgery was scheduled to occur within 6 weeks after the last neoadjuvant treatment; patients could then receive optional adjuvant therapy (up to four cycles of chemotherapy, radiotherapy, or both) per ...

IO Biotech (IOBT) announced it has completed enrollment in its neoadjuvant/adjuvant Phase 2 basket trial, IOB-032/PN-E40. The trial is studying ...

Researchers found that receipt of neoadjuvant and adjuvant chemotherapy were associated with inadequate ovarian function suppression. Researchers say they have identified several factors that may be ...

The investigators evaluated the feasibility and capacity of the RAD51 test to predict which patients with early-stage breast ...

The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...